Imugene Limited

DB:ILA Stock Report

Market Cap: €58.7m

Imugene Management

Management criteria checks 3/4

Imugene's CEO is Leslie Chong, appointed in Nov 2016, has a tenure of 7.67 years. total yearly compensation is A$2.38M, comprised of 33.1% salary and 66.9% bonuses, including company stock and options. directly owns 0.96% of the company’s shares, worth €563.32K. The average tenure of the management team and the board of directors is 2.3 years and 7.1 years respectively.

Key information

Leslie Chong

Chief executive officer

AU$2.4m

Total compensation

CEO salary percentage33.14%
CEO tenure9yrs
CEO ownership1.0%
Management average tenure2.3yrs
Board average tenure7.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Leslie Chong's remuneration changed compared to Imugene's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025AU$2mAU$788k

-AU$69m

Mar 31 2025n/an/a

-AU$99m

Dec 31 2024n/an/a

-AU$129m

Sep 30 2024n/an/a

-AU$139m

Jun 30 2024AU$2mAU$780k

-AU$150m

Mar 31 2024n/an/a

-AU$119m

Dec 31 2023n/an/a

-AU$89m

Sep 30 2023n/an/a

-AU$64m

Jun 30 2023AU$2mAU$750k

-AU$38m

Mar 31 2023n/an/a

-AU$39m

Dec 31 2022n/an/a

-AU$40m

Sep 30 2022n/an/a

-AU$39m

Jun 30 2022AU$1mAU$600k

-AU$38m

Mar 31 2022n/an/a

-AU$33m

Dec 31 2021n/an/a

-AU$27m

Sep 30 2021n/an/a

-AU$23m

Jun 30 2021AU$789kAU$408k

-AU$18m

Mar 31 2021n/an/a

-AU$15m

Dec 31 2020n/an/a

-AU$12m

Sep 30 2020n/an/a

-AU$11m

Jun 30 2020AU$733kAU$375k

-AU$11m

Mar 31 2020n/an/a

-AU$10m

Dec 31 2019n/an/a

-AU$9m

Sep 30 2019n/an/a

-AU$8m

Jun 30 2019AU$777kAU$350k

-AU$8m

Compensation vs Market: Leslie's total compensation ($USD1.55M) is above average for companies of similar size in the German market ($USD494.52K).

Compensation vs Earnings: Leslie's compensation has been consistent with company performance over the past year.

CEO

Leslie Chong

9yrs
Tenure
AU$2,377,296
Compensation

Ms. Leslie Chong served as Non-Executive Director of Chimeric Therapeutics Limited since August 28, 2020 until July 2023. Ms. Chong has been the Chief Executive Officer of Imugene Limited since November 21...

Leadership Team

NamePositionTenureCompensationOwnership
Paul Hopper
Executive Chairman13.1yrsAU$547.31k4.23%
€ 2.5m
Leslie Chong
CEO, MD & Executive Director9yrsAU$2.38m0.96%
€ 563.3k
Darren Keamy
CFO & Company Secretaryless than a yearAU$408.91kno data
Bradley Glover
Chief Operating Officer2.3yrsAU$1.74m0.00065%
€ 381.5
John Byon
Chief Medical Officer2.2yrsAU$850.12k0.00065%
€ 381.5
Ursula McCurry
Chief Clinical Operations Officer3.8yrsno datano data
2.3yrs
Average Tenure
56yo
Average Age

Experienced Management: ILA's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul Hopper
Executive Chairman13.1yrsAU$547.31k4.23%
€ 2.5m
Leslie Chong
CEO, MD & Executive Director7.7yrsAU$2.38m0.96%
€ 563.3k
Kimberlee Drapkin
Non-Executive Director2.4yrsAU$139.65k0.0062%
€ 3.6k
Yuman Fong
Chair of Oncolytic Virotherapy Scientific Advisory Board6yrsno data0.22%
€ 130.6k
Neil Segal
Member of Scientific Advisory Board11.6yrsno datano data
Josep Tabernero Caturla
Member of Scientific Advisory Board7.1yrsno datano data
Yelena Janjigian
Scientific Advisory Board Member9.6yrsno datano data
Lesley Cooper
Independent Non-Executive Director6.6yrsAU$132.96k0.21%
€ 121.0k
Peter Schmid
Member of Scientific Advisory Board7.9yrsno datano data
Tanios Bekaii-Saab
Member of Scientific Advisory Board7.2yrsno datano data
Pravin T. Kaumaya
Member of Scientific Advisory Board7.1yrsno datano data
Prasad Adusumilli
Member of Scientific Advisory Board6yrsno datano data
7.1yrs
Average Tenure
64yo
Average Age

Experienced Board: ILA's board of directors are considered experienced (7.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/03 01:40
End of Day Share Price 2025/10/24 00:00
Earnings2025/06/30
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Imugene Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Hunter DiamondDiamond Equity Research LLC
Dennis HulmeEdison Investment Research